Biotech Top 50 Companies — Shixi Bio, Moon Bio, and Zhaoke Ophthalmology Announce Recent Funding Rounds and Strategic Advancements

Top 50 Biotech Startups of the Year – RECORNA (Guangzhou) Biotechnology Co., Ltd.(hereinafter referred to as "RECORNA"),A research and development company that develops innovative drugs through targeted RNA technology announced that it has completed the first closing of an angel+ round of financing worth tens of millions of yuan.This round of financing was jointly led by Beijing Life Science Park Ventures, Tiantu Investment, and Yiyi Capital, with follow-on investments from BeiGene BioIsland Innovation Center (hereinafter referred to as "BeiGene Innovation Center"), and continued support from Xiaochi Capital. Heryue Capital served as the exclusive financial advisor. The funds will be used for the research and development of the company's core projects, clinical applications, and team expansion.

RecoRNA is a nucleic acid drug research and development company that focuses on developing innovative drugs for indications lacking effective conventional treatments through its RNA editing technology platform. The targeted therapeutic areas include cardiovascular and cerebrovascular diseases, neurological disorders, respiratory conditions, anti-aging, and other fields with significant unmet clinical needs. Relying on the technology transfer from Professor Zhang Rui's laboratory at Sun Yat-sen University's School of Life Sciences, RecoRNA has established an independent RNA editing platform with proprietary intellectual property rights. Located in the Bio Island Innovation Center in Guangzhou, the company has built a comprehensive R&D platform encompassing drug discovery, biological validation, and delivery system development.

Top 50 Biotech Pioneering Enterprises of the Third Edition — Guangzhou Colony Biotechnology Co., Ltd.("MooBio" hereinafter)Announced that it has recently completed a C+ round of financing worth 300 million yuan, exclusively invested by SDIC Julive.This round of financing also marks the second time that Guangzhou Colony Biotechnology Co., Ltd. has received support from a national team fund, following the introduction of the SDIC Venture Capital Fund in the C-round financing. The new round of funding will mainly be used to advance the scaled production and commercialization of more bio-innovative products, as well as to expand the company's proprietary commercial microbial strain library and component library, and further improve its bio-manufacturing technology platform.

Guangzhou Colony Biotechnology Co., Ltd. is a platform-based biotechnology company specializing in microbial discovery and bio-manufacturing. It has established a complete industrial technology system for the discovery, screening, modification, and application of microorganisms. The company also owns the world's largest and most biodiverse microbial strain library and genetic component library, preserving over 270,000 microbial strains with independent intellectual property rights. Relying on high-standard strain resources, in-depth microbiome research and data mining, as well as a leading synthetic biology technology platform, the company efficiently develops and provides top-tier bio-based products and solutions for niche markets such as bio-agriculture, biopharmaceuticals, and microbial proteins.

Recently,Top 50 Biotech Leader of the Year — Zhaoke Ophthalmology LimitedAbbreviated as "Zhaoke Ophthalmology")Announced the signing of a strategic partnership agreement with Wenzhou EyeVision International Innovation Center ("China Eye Valley"), a leading ophthalmic health R&D institution and industry platform in China., aiming to develop innovative and generic drugs for major ophthalmic indications, co-build the "China Eye Valley - Zhaoke Ophthalmology Innovative Drug Research Institute," and jointly promote the development of China's eye health industry.

Zhaoke Ophthalmology Limited is a leading ophthalmic pharmaceutical company dedicated to the research, development, manufacturing, and commercialization of ophthalmic therapies to address significant unmet global healthcare needs. Zhaoke Ophthalmology has established a pipeline of drug candidates comprising both innovative and generic drugs, covering six major ophthalmic indications affecting the anterior and posterior segments of the eye.